Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2021 15:59 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; November 22, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
November 22, 2021 15:53 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; November 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 7,959 restricted stock units to members of...
November 16, 2021 13:11 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 16, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 17,862 shares as a consequence of the exercise of employee warrants. The...
November 10, 2021 11:00 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2021

November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Genmab and Seagen Inc....
November 04, 2021 16:24 ET | Source: Genmab A/S

Genmab Improves its 2021 Financial Guidance

Company Announcement Genmab improves its 2021 financial guidance COPENHAGEN, Denmark; November 4, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance...
November 04, 2021 09:07 ET | Source: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

Media Release Copenhagen, Denmark, November 4, 2021 Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody®-CD3xCD20) in combination with other treatments in...
November 03, 2021 10:19 ET | Source: Genmab A/S

Genmab to Present at Jefferies Virtual London Healthcare Conference

Media ReleaseCopenhagen, Denmark, November 03, 2021Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will take part in a fireside chat at the Jefferies Virtual London...
October 19, 2021 06:29 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
October 15, 2021 13:05 ET | Source: Genmab A/S

Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy

Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe...
October 07, 2021 14:55 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; October 7, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537...